Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors

Interleukin‐6 (IL‐6) may play a pathological role in rheumatoid arthritis (RA) and periodontitis. Although the efficacy of medication with IL‐6 receptor inhibitor, tocilizumab (TCZ), has been demonstrated in the treatment of RA, very little is known about whether TCZ therapy affects periodontitis. T...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Exp Dent Res
Asıl Yazarlar: Kobayashi, Tetsuo, Ito, Satoshi, Kobayashi, Daisuke, Kojima, Anri, Shimada, Atsushi, Narita, Ichiei, Murasawa, Akira, Nakazono, Kiyoshi, Yoshie, Hiromasa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839195/
https://ncbi.nlm.nih.gov/pubmed/29744142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cre2.11
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller